The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | The mutational profile in patients with CLL treated with acalabrutinib or ibrutinib
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the mutational profile of patients with chronic lymphocytic leukemia (CLL) who were treated on the ELEVATE-RR trial (NCT02477696). This trial compared acalabrutinib to ibrutinib in previously treated high-risk patients. The study revealed mutational changes at the time of relapse, highlighting ongoing clonal evolution during relapse and the need for further investigation. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Newave, Loxo, Beigene, AstraZeneca, Abbvie, Janssen, Pharmacyclics; Research Funding: Schrodinger, Morphosys, Karyopharm, Janssen, Pharmacyclics.
